Trial Outcomes & Findings for Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury (NCT NCT02158494)

NCT ID: NCT02158494

Last Updated: 2019-05-03

Results Overview

SOT assesses the ability to use visual, proprioceptive, and vestibular cues to maintain postural stability. Subjects stand on dual-force plates and the anterior-posterior sway is recorded. 6 conditions are tested (3, 20-sec trials each): Eyes open on firm surface; Eyes closed on firm surface; Eyes open with sway referenced visual surround; Eyes open on sway referenced support surface; Eyes closed on sway referenced support surface; Eyes open on sway referenced support surface and surround. A composite score is generated by the NeuroCom BalanceMaster System using an algorithm to calculate the composite score from each of the 3 serial repetitions for each of the 6 conditions (a total of 18 sub-scores). The calculated composite score ranges from 0 to 100 points; 0 is complete failure, 100 is perfect stability, 70 is the lower limit normal. Group mean score for each time-point is reported.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

44 participants

Primary outcome timeframe

Baseline, 2, 14, and 26 weeks

Results posted on

2019-05-03

Participant Flow

13 subjects provided consent but did not enroll in the study at sites under UW-Madison purview.

Participant milestones

Participant milestones
Measure
Neurostimulation
Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training)
Control (Non-zero, Minimally Perceivable Stimulation)
Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
Overall Study
STARTED
22
22
Overall Study
COMPLETED
22
21
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Neurostimulation
n=22 Participants
Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
Total
n=43 Participants
Total of all reporting groups
Age, Continuous
54.05 years
STANDARD_DEVIATION 5.91 • n=99 Participants
53.24 years
STANDARD_DEVIATION 10.55 • n=107 Participants
53.89 years
STANDARD_DEVIATION 9.14 • n=206 Participants
Sex: Female, Male
Female
14 Participants
n=99 Participants
14 Participants
n=107 Participants
28 Participants
n=206 Participants
Sex: Female, Male
Male
8 Participants
n=99 Participants
7 Participants
n=107 Participants
15 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
n=99 Participants
20 Participants
n=107 Participants
40 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=99 Participants
0 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
White
19 Participants
n=99 Participants
20 Participants
n=107 Participants
39 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline, 2, 14, and 26 weeks

SOT assesses the ability to use visual, proprioceptive, and vestibular cues to maintain postural stability. Subjects stand on dual-force plates and the anterior-posterior sway is recorded. 6 conditions are tested (3, 20-sec trials each): Eyes open on firm surface; Eyes closed on firm surface; Eyes open with sway referenced visual surround; Eyes open on sway referenced support surface; Eyes closed on sway referenced support surface; Eyes open on sway referenced support surface and surround. A composite score is generated by the NeuroCom BalanceMaster System using an algorithm to calculate the composite score from each of the 3 serial repetitions for each of the 6 conditions (a total of 18 sub-scores). The calculated composite score ranges from 0 to 100 points; 0 is complete failure, 100 is perfect stability, 70 is the lower limit normal. Group mean score for each time-point is reported.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)
Baseline
42.77 score on a scale
Standard Deviation 17.54
36.24 score on a scale
Standard Deviation 16.09
NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)
Week 2
63.73 score on a scale
Standard Deviation 15.06
62.00 score on a scale
Standard Deviation 22.32
NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)
Week 14
70.89 score on a scale
Standard Deviation 11.45
71.21 score on a scale
Standard Deviation 16.95
NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)
Week 26
74.83 score on a scale
Standard Deviation 11.86
71.50 score on a scale
Standard Deviation 17.50

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

A 22-item subjective inventory of TBI symptoms where symptoms are scored on a scale of 0 (none) to 4 (very severe). Lower scores indicate decreased symptoms. Group mean change from baseline at 2, 14, and 26 weeks is reported. The range of possible scores if from 0 to 88. The results are reported as a change from baseline.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Neurobehavioral Symptom Inventory Over Baseline
Week 2
-13.52 score on a scale
Standard Deviation 9.17
-7.52 score on a scale
Standard Deviation 13.58
Change in Neurobehavioral Symptom Inventory Over Baseline
Week 14
-10.47 score on a scale
Standard Deviation 10.12
-7.10 score on a scale
Standard Deviation 9.83
Change in Neurobehavioral Symptom Inventory Over Baseline
Week 26
-9.94 score on a scale
Standard Deviation 15.49
-8.40 score on a scale
Standard Deviation 10.46

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Measures walking speed over ground. The six-minute walk test (6MWT) measures the distance in meters an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Change in 6MWT over baseline for each time point is reported.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in 6-Minute Walk Test (6MWT) Over Baseline
Week 2
33.06 meters
Standard Deviation 75.01
19.02 meters
Standard Deviation 39.41
Change in 6-Minute Walk Test (6MWT) Over Baseline
Week 14
72.27 meters
Standard Deviation 79.97
62.30 meters
Standard Deviation 51.04
Change in 6-Minute Walk Test (6MWT) Over Baseline
Week 26
76.81 meters
Standard Deviation 95.41
74.38 meters
Standard Deviation 49.21

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Assesses walking, walking with head turns, over and around obstacles, and stairs. Dynamic Gait Index - A semiquantitative tool used to evaluate a patient's ability to modify gait by changing task demands, esp. in patients with dizziness and balance deficits. This test is used to identify patients, esp. older adults, who are predisposed to falling. Participants are graded from 0 (low function) to 3 (high function) on 8 tasks: normal walking, their ability to vary walking speed, turn their heads, turn their bodies, step over and around obstacles, climb stairs, turn while walking. The range of scores is 0-24, higher scores indicate higher function, with a score of 24 considered Normal. Change from baseline to 2, 14, and 26 weeks is reported.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Dynamic Gait Index (DGI) Over Baseline
Week 2
2.23 score on a scale
Standard Deviation 2.88
1.76 score on a scale
Standard Deviation 2.72
Change in Dynamic Gait Index (DGI) Over Baseline
Week 14
3.58 score on a scale
Standard Deviation 3.53
3.42 score on a scale
Standard Deviation 3.11
Change in Dynamic Gait Index (DGI) Over Baseline
Week 26
4.12 score on a scale
Standard Deviation 3.67
3.45 score on a scale
Standard Deviation 3.41

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Assesses short- and long-term verbal memory by evaluating a series of recall and recognition tasks. The test is scored via computer algorithm. A score of 50 represents is equal to the population mean, the normal range is between 40-60 (ie. +/- 1 SD from the mean). The total range of possible scores is 0 (no recalled words) to 100 (all correct). Change in score over baseline at 2, 14, and 26 weeks is reported.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in California Verbal Learning Test (CVLT) Over Baseline
Week 2
8.95 units on a scale
Standard Deviation 8.48
9.71 units on a scale
Standard Deviation 6.63
Change in California Verbal Learning Test (CVLT) Over Baseline
Week 14
9.00 units on a scale
Standard Deviation 11.34
11.30 units on a scale
Standard Deviation 9.40
Change in California Verbal Learning Test (CVLT) Over Baseline
Week 26
10.28 units on a scale
Standard Deviation 11.79
11.00 units on a scale
Standard Deviation 9.70

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

A short, reliable, 18-question instrument for assessment of psychological distress (anxiety, depression, \& somatization) in a clinical population. It is scored from 0-4, with a total range of possible scores 0-72 where higher scores indicate more distress.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Brief Symptom Inventory 18 (BSI 18) Over Baseline
Week 14
-4.16 units on a scale
Standard Deviation 9.41
-2.95 units on a scale
Standard Deviation 6.13
Change in Brief Symptom Inventory 18 (BSI 18) Over Baseline
Week 2
-5.32 units on a scale
Standard Deviation 9.10
-2.38 units on a scale
Standard Deviation 7.53
Change in Brief Symptom Inventory 18 (BSI 18) Over Baseline
Week 26
-7.72 units on a scale
Standard Deviation 10.15
-2.50 units on a scale
Standard Deviation 6.93

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Assesses visual spatial abilities. The Symbol Search and Coding WAIS-IV subtests measure Processing Speed, an indicator of the rate of cognitive processing and creating an appropriate response output. The tasks require attending to visual material, visual scanning and perception, spatial organization, hand-eye coordination, and paired associative learning. The raw score (processing speed for each test) is converted to a scaled score 1-10 for each and summed for a total possible score of 2-20, the higher the score, the more improved the processing speed. Change in score from baseline to 2, 14, and 26 weeks are reported.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over Baseline
Week 2
0.95 score on a scale
Standard Deviation 2.38
1.14 score on a scale
Standard Deviation 2.29
Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over Baseline
Week 14
1.11 score on a scale
Standard Deviation 2.90
1.25 score on a scale
Standard Deviation 2.02
Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over Baseline
Week 26
1.78 score on a scale
Standard Deviation 2.44
1.20 score on a scale
Standard Deviation 2.35

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline at 2,14, and 26 weeks

Subjective inventory of sleep habits, duration and quality. It is scored from 7 components (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction) to provide a global PSQI score. Most items are scored from 0-3 where 3 is a negative extreme, therefore lower cumulative scores are indicative of improved sleep habits. The total range of scores is from 0-21.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline
Week 2
8.682 score on a scale
Standard Deviation 5.213
7.810 score on a scale
Standard Deviation 5.698
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline
Week 26
8.294 score on a scale
Standard Deviation 5.084
8.238 score on a scale
Standard Deviation 5.272
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline
Baseline
9.318 score on a scale
Standard Deviation 4.874
9.182 score on a scale
Standard Deviation 4.934
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline
Week 14
8.611 score on a scale
Standard Deviation 4.742
8.714 score on a scale
Standard Deviation 5.349

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Assesses frequency \& severity of headaches via a 25-item questionnaire where an answer of 'yes' = 4 points, 'sometimes' = 2 points, and 'no' = 0 points. The lower the score, the less frequent and severe the symptoms. The range of possible scores is 0 to 100. The results are reported as a change from baseline.

Outcome measures

Outcome measures
Measure
Neurostimulation
n=22 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Control (Non-zero, Minimally Perceivable Stimulation)
n=21 Participants
This randomized double blind controlled study will enroll a total of 44 subjects (M \& F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting.
Change in Headache Disability Index (HDI) From Baseline
Week 2
-16.00 score on a scale
Standard Deviation 23.56
-4.38 score on a scale
Standard Deviation 20.15
Change in Headache Disability Index (HDI) From Baseline
Week 14
-9.79 score on a scale
Standard Deviation 18.02
-11.00 score on a scale
Standard Deviation 20.62
Change in Headache Disability Index (HDI) From Baseline
Week 26
-14.78 score on a scale
Standard Deviation 21.17
-13.60 score on a scale
Standard Deviation 23.48

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Measures muscle activation patterns during gait.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Change from Baseline at 2,14, and 26 weeks

Measures eye movement control under 3 static (x and y axis fixation, spontaneous nystagmus), and 3 dynamic conditions (random saccade, smooth pursuit, optokinetic nystagmus).

Outcome measures

Outcome data not reported

Adverse Events

Neurostimulation

Serious events: 3 serious events
Other events: 11 other events
Deaths: 0 deaths

Minimally Perceivable Stimulation

Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Neurostimulation
n=22 participants at risk
Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Balance and Gait Training using neurostimulation modulation.: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Minimally Perceivable Stimulation
n=21 participants at risk
Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Balance and Gait Training using neurostimulation modulation.: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
General disorders
General disorders and administration site conditions - Other, specify
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Hepatobiliary disorders
Gallbladder Obstruction
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Renal and urinary disorders
Urinary Tract Obstruction
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Renal and urinary disorders
Prostate cancer
0.00%
0/22 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)

Other adverse events

Other adverse events
Measure
Neurostimulation
n=22 participants at risk
Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Balance and Gait Training using neurostimulation modulation.: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Minimally Perceivable Stimulation
n=21 participants at risk
Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Balance and Gait Training using neurostimulation modulation.: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
General disorders
General Pain
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 2 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
18.2%
4/22 • Number of events 4 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
9.5%
2/21 • Number of events 2 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Nervous system disorders
Headache
13.6%
3/22 • Number of events 3 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
14.3%
3/21 • Number of events 6 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Injury, poisoning and procedural complications
Fracture
9.1%
2/22 • Number of events 2 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Nervous system disorders
Dizziness
0.00%
0/22 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Infections and infestations
Infection
13.6%
3/22 • Number of events 3 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Injury, poisoning and procedural complications
Poisoning
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Surgical and medical procedures
Surgery
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Renal and urinary disorders
Kidney Stones
0.00%
0/22 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
4.8%
1/21 • Number of events 2 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Metabolism and nutrition disorders
Diabetic Shock
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Gastrointestinal disorders
Vomiting and Diahrrea
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Metabolism and nutrition disorders
Dehydration
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
Injury, poisoning and procedural complications
Laceration
4.5%
1/22 • Number of events 1 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)
0.00%
0/21 • 26 weeks
* Category - the medical terminology for the adverse event or unanticipated problem category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx) * AE Detail - a detailed description of the severity of the category from the Safety Profiler list of Common Terminology Criteria for Adverse Events (http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx)

Additional Information

Mitchell Tyler

University of Wisconsin - Madison

Phone: 608-262-5112

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place